The European modern insulin market can be segmented by insulin type, yielding three segments: long-acting insulin, rapid-acting insulin and premixed insulin. In 2015, the largest segment in the total modern insulin market was the long-acting insulin segment, which represented nearly 50% of the total market value. Patent expirations and the introduction of new products will lead to higher unit sales growth in this segment, relative to the rapid-acting insulin and premixed insulin segments. Combined with modest appreciation of ASP, it is projected that long-acting insulin will be the fastest growing segment in the total modern insulin market over the forecast period.
Insulin is a hormone that causes glucose uptake from the blood through the cells of the liver, muscle and fat tissue to be stored as glycogen in the liver and muscle. Type 1 diabetics’ immune systems destroy pancreatic beta cells: the only cells that can make insulin. The body therefore fails to produce insulin and cannot naturally convert food into energy. Type 2 diabetics have a resistance to insulin, and cells are not able to use the insulin present in the body. The need for insulin increases to the point that the pancreas can no longer produce it. Insulin is therefore a mode of treating both type 1 and type 2 diabetes.
'
TABLE OF CONTENTS I
LIST OF FIGURES IV
LIST OF CHARTS VI
EXECUTIVE SUMMARY 1
EUROPEAN MARKET FOR DIABETES MONITORING, TREATMENT AND DRUG DELIVERY 1
COMPETITIVE ANALYSIS 4
MARKET TRENDS 6
MARKET DEVELOPMENTS 8
MARKETS INCLUDED 9
KEY REPORT UPDATES 10
VERSION HISTORY 10
RESEARCH METHODOLOGY 11
1.1 RESEARCH SCOPE 11
1.2 IDATA’S 9-STEP METHODOLOGY 11
Step 1: Project Initiation & Team Selection 11
Step 2: Prepare Data Systems and Perform Secondary Research 13
Step 3: Preparation for Interviews & Questionnaire Design 14
Step 4: Performing Primary Research 15
Step 5: Research Analysis: Establishing Baseline Estimates 17
Step 6: Market Forecast and Analysis 18
Step 7: Identify Strategic Opportunities 20
Step 8: Final Review and Market Release 21
Step 9: Customer Feedback and Market Monitoring 22
DISEASE OVERVIEW 23
2.1 INTRODUCTION 23
2.1.1 Types of Diabetes 23
2.1.2 Diabetes Complications 25
2.1.3 Risk Factors Associated with Type 1 and Type 2 Diabetes 27
2.1.4 Signs and Symptoms 28
2.1.5 Diabetes Monitoring 29
2.1.6 Treatment 31
2.1.7 Drug Delivery Systems 33
COUNTRY PROFILES 35
3.1 INTRODUCTION 35
3.1.1.1 Population 35
3.1.1.2 GDP Per Capita 35
3.1.1.3 Units 35
3.2 GERMANY 36
3.3 FRANCE 37
3.4 UNITED KINGDOM 38
3.5 ITALY 39
3.6 SPAIN 40
3.7 BENELUX 41
3.8 SCANDINAVIA 42
3.9 AUSTRIA 43
3.10 SWITZERLAND 44
3.11 PORTUGAL 45
MODERN INSULIN MARKET 46
4.1 INTRODUCTION 46
4.1.1 Insulin Types 46
4.1.1.1 Rapid-Acting Insulin Analogs 46
4.1.1.2 Regular Human Insulin 47
4.1.1.3 Intermediate-Acting Insulin Analogs 47
4.1.1.4 Long-Acting Insulin Analogs 47
4.1.1.5 Ultra-Long-Acting Insulin Analogs 47
4.2 MARKET OVERVIEW 48
4.3 MARKET ANALYSIS AND FORECAST 52
4.3.1 Total Modern Insulin Market 52
4.3.2 Long-Acting Insulin Market 59
4.3.3 Rapid-Acting Insulin Market 66
4.3.4 Premixed Insulin Market 74
4.4 DRIVERS AND LIMITERS 82
4.4.1 Market Drivers 82
4.4.2 Market Limiters 83
4.5 COMPETITIVE MARKET SHARE ANALYSIS 85
ABBREVIATIONS 88
Chart 1 1: Diabetes Diagnosis, Treatment and Drug Delivery, Europe, 2012 – 2022 3
Chart 1 2: Diabetes Diagnosis, Treatment and Drug Delivery Market Overview, Europe, 2012 & 2022 3
Chart 3 1: Country Profile, Germany, 2015 36
Chart 3 2: Country Profile, France, 2015 37
Chart 3 3: Country Profile, United Kingdom, 2015 38
Chart 3 4: Country Profile, Italy, 2015 39
Chart 3 5: Country Profile, Spain, 2015 40
Chart 3 6: Country Profile, Benelux, 2015 41
Chart 3 7: Country Profile, Scandinavia, 2015 42
Chart 3 8: Country Profile, Austria, 2015 43
Chart 3 9: Country Profile, Switzerland, 2015 44
Chart 3 10: Country Profile, Portugal, 2015 45
Chart 4 1: Total Modern Insulin Market by Segment, Europe, 2015 50
Chart 4 2: Total Modern Insulin Market Breakdown, Europe, 2015 51
Chart 4 3: Total Modern Insulin Market Breakdown, Europe, 2022 51
Chart 4 4: Total Modern Insulin Market, Europe, 2012 – 2022 (€M) 53
Chart 4 5: Long-Acting Insulin Market, Europe, 2012 – 2022 (€M) 60
Chart 4 6: Rapid-Acting Insulin Market, Europe, 2012 – 2022 (€M) 68
Chart 4 7: Premixed Insulin Market, Europe, 2012 – 2022 (€M) 76
Chart 4 8: Leading Competitors, Insulin Market, Europe, 2015 87
Figure 1 1: Diabetes Diagnosis, Treatment and Drug Delivery Competitor Market Share Ranking by Segment, Europe, 2015 (1 of 2) 4
Figure 1 2: Diabetes Diagnosis, Treatment and Drug Delivery Competitor Market Share Ranking by Segment, Europe, 2015 (2 of 2) 4
Figure 1 3: Companies Researched in this Report, Europe, 2015 5
Figure 1 4: Factors Impacting the Diabetes Diagnosis, Treatment and Drug Delivery Market by Segment, Europe (1 of 2) 6
Figure 1 5: Factors Impacting the Diabetes Diagnosis, Treatment and Drug Delivery Market by Segment, Europe (2 of 2) 7
Figure 1 6: Recent Events in the Diabetes Diagnosis, Treatment and Drug Delivery Market, Europe, 2012 – 2016 8
Figure 2 1: Major Types of Diabetes and Related Pathologies, Europe, 2015 24
Figure 2 2: Risk Factors Associated with Type 1 and Type 2 Diabetes, Europe, 2015 28
Figure 2 3: Signs and Symptoms Associated with Type 1 and Type 2 Diabetes, Europe, 2015 29
Figure 4 1: Onset, Peak and Duration of Insulin Types, Europe, 2015 47
Figure 4 2: Total Modern Insulin Market by Segment, Europe, 2012 – 2022 (€M) 49
Figure 4 3: Total Modern Insulin Market by Segment, Europe, 2012 – 2022 (US$M) 49
Figure 4 4: Total Modern Insulin Market, Europe, 2012 – 2022 (€ and US$) 53
Figure 4 5: Units Sold (Million mL) by Country, Total Modern Insulin Market, Europe, 2012-2022 54
Figure 4 6: Average Sales Price (per mL) by Country, Total Modern Insulin Market, Europe, 2012-2022 (€) 55
Figure 4 7: Average Sales Price (per mL) by Country, Total Modern Insulin Market, Europe, 2012-2022 (US$) 56
Figure 4 8: Total Modern Insulin Market by Country, Europe, 2012-2022 (€M) 57
Figure 4 9: Total Modern Insulin Market by Country, Europe, 2012-2022 (US$M) 58
Figure 4 10: Long-Acting Insulin Market, Europe, 2012 – 2022 (€ and US$) 60
Figure 4 11: Units Sold (Million mL) by Country, Long-Acting Insulin Market, Europe, 2012-2022 61
Figure 4 12: Average Sales Price (per mL) by Country, Long-Acting Insulin Market, Europe, 2012-2022 (€) 62
Figure 4 13: Average Sales Price (per mL) by Country, Long-Acting Insulin Market, Europe, 2012-2022 (US$) 63
Figure 4 14: Long-Acting Insulin Market by Country, Europe, 2012-2022 (€M) 64
Figure 4 15: Long-Acting Insulin Market by Country, Europe, 2012-2022 (US$M) 65
Figure 4 16: Rapid-Acting Insulin Market, Europe, 2012 – 2022 (€ and US$) 67
Figure 4 17: Units Sold (Million mL) by Country, Rapid-Acting Insulin Market, Europe, 2012-2022 69
Figure 4 18: Average Sales Price (per mL) by Country, Rapid-Acting Insulin Market, Europe, 2012-2022 (€) 70
Figure 4 19: Average Sales Price (per mL) by Country, Rapid-Acting Insulin Market, Europe, 2012-2022 (US$) 71
Figure 4 20: Rapid-Acting Insulin Market by Country, Europe, 2012-2022 (€M) 72
Figure 4 21: Rapid-Acting Insulin Market by Country, Europe, 2012-2022 (US$M) 73
Figure 4 22: Premixed Insulin Market, Europe, 2012 – 2022 (€ and US$) 75
Figure 4 23: Units Sold (Million mL) by Country, Premixed Insulin Market, Europe, 2012-2022 77
Figure 4 24: Average Sales Price (per mL) by Country, Premixed Insulin Market, Europe, 2012-2022 (€) 78
Figure 4 25: Average Sales Price (per mL) by Country, Premixed Insulin Market, Europe, 2012-2022 (US$) 79
Figure 4 26: Premixed Insulin Market by Country, Europe, 2012-2022 (€M) 80
Figure 4 27: Premixed Insulin Market by Country, Europe, 2012-2022 (US$M) 81
Figure 4 28: Drivers and Limiters, Insulin Market, Europe, 2015 84
Figure 4 29: Leading Competitors, Modern Insulin Market, Europe, 2015 86
Novo Nordisk
Sanofi
Roche
Johnson & Johnson
Eli Lilly
Abbott
Ascensia
Becton Dickinson
Medtronic
Menarini
DexCom
Ypsomed
Insulet
Artsana
B. Braun
Terumo
Others include: Abbott, AgaMatrix, Artsana, Apollo, BBI Healthcare, B. Braun, Berger, Beurer, Boehringer Ingelheim, Cellnovo, Codan, Comfort Point, Dario Health, Elektronika, Entra Health Systems, GlucoRx, GlucoZen, Infopia, Medtronic, MED TRUST, Medisana, Menarini, Merck Serono, MSP bodmann, Neon Diagnostics, NordicInfu Care, Novalab Ibérica, Novico, Owen Mumford, Pentaferte, Roche, Sanofi, SD BIOSENSOR, SFM Medical, Smiths Medical, Spirit Healthcare, Sooil, Trividia Health, Ypsomed, etc.
